Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2022 | Selecting patients with AL amyloidosis for autoHSCT

Iuliana Vaxman • 12 Jun 2022
EHA 2022
Amyloidosis Rare Diseases Antibodies Daratumumab
ANDROMEDA

Iuliana Vaxman, MD, Mayo Clinic, Rochester, MN, discusses the role of autologous hematopoietic stem cell transplantation (autoHSCT) in immunoglobulin light-chain (AL) amyloidosis. Dr Vaxman explains that only 20% of patients with AL amyloidosis are eligible for autoHSCT and it is therefore crucial to select the right patients to undergo this treatment. However, there is currently no data outlining patient selection criteria in this setting. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

More from Iuliana Vaxman

3:18
Safety and efficacy of daratumumab, carfilzomib, pomalidomide & elotuzumab in POEMS syndrome
Iuliana Vaxman • 12 Jun 2022
1:38
The safety and efficacy of belantamab mafodotin in R/R multiple myeloma in the real world
Iuliana Vaxman • 12 Jun 2022

Related Videos

3:18
Immune-mediated bone marrow failure diseases & their pathophysiology: aplastic anemia, LR-MDS & PNH
Carlo Dufour • 15 Apr 2024
1:11
Personalized risk assessment for transplantation in primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
1:18
Autologous gene editing using the CRISPR system to treat primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
0:58
Hematological manifestations associated with primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals